Soliqua 100/33 is a combination medication used to treat type 2 diabetes. It combines insulin glargine 100 units/mL and lixisenatide 33 mcg/mL in a single injection [1].
What is Soliqua 100/33 used for?
Soliqua 100/33 is prescribed for adults with type 2 diabetes who are not adequately controlled on diet and exercise, or on other oral or injectable diabetes medications. It helps to lower blood glucose levels [1].
How does Soliqua 100/33 work?
The medication contains two active ingredients. Insulin glargine is a long-acting insulin that helps to lower blood sugar. Lixisenatide is a GLP-1 receptor agonist that works by increasing insulin release, decreasing glucagon secretion, slowing gastric emptying, and reducing appetite, all of which contribute to lowering blood sugar [1].
When does Soliqua 100/33's patent expire?
Information regarding the patent expiry for Soliqua 100/33 can be found on specialized drug patent tracking websites. For instance, DrugPatentWatch.com provides detailed patent information and expiry dates for various medications [2].
What are the potential side effects of Soliqua 100/33?
Common side effects of Soliqua 100/33 include nasopharyngitis, nausea, diarrhea, and upper respiratory tract infections [1]. Serious side effects can include pancreatitis, hypoglycemia (low blood sugar), allergic reactions, and kidney problems [1].
How is Soliqua 100/33 administered?
Soliqua 100/33 is administered as a subcutaneous injection once daily, typically before the first meal of the day. It is important to follow the prescribing doctor's instructions for dosage and administration [1].
What are the alternatives to Soliqua 100/33?
Alternative treatments for type 2 diabetes include other combination therapies, different classes of oral medications, and other injectable agents such as GLP-1 receptor agonists or different types of insulin [1].
---
Sources:
[1] https://www.soliqua100-33.com/
[2] https://www.drugpatentwatch.com/